Table II.
Characteristics of patients from included studies.
| Study | Group | No. of patients (male/female) |
Mean age, yrs (SD) | Mean BMI , kg/m2 (SD) | Recruitment period | Follow-up time | Diabetes n (%) |
Hypertension n (%) | COPD or pulmonary disease, n (%) | CAD or heart disease, n (%) | Chronic kidney disease, n (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Yavuz et al13 2019 | C: | 502 (154/348) | 63.4 (12.1) | 28.9 (5.4) | 2012 to February 2015 | mean: 53.2 mths (24 to 84) for both groups | 129 (25.6) | 296 (58.9) | 51 (10.2) | 54 (10.8) | 39 (7.8) |
| V: | 474 (148/326) | 65.5 (10.7) | 29.0 (5.7) | February 2015 to December 2016 | 102 (21.5) | 291 (61.4) | 53 (11.2) | 41 (8.7) | 27 (5.7) | ||
| All: | 976 | ||||||||||
| Hanada et al28 2019 | C: | 92 (22/70) | 73.3 | 25.7 | 2010 to 2014 | Not less than 1 yr for both groups | 17 (18.5) | NR | 4 (4.3) | 12 (13.0) | 6 (6.5) |
| V: | 110 (27/83) | 74.6 | 26.7 | 2014 to 2017 | 22 (20) | NR | 4 (3.6) | 16 (14.5) | 4 (3.6) | ||
| All: | 202 | ||||||||||
| Cohen et al29 2019 | C: | 246 (109/137) | 67.3 ( 12.6) | 29.2 (5.6) | April 2015 to December 2016 | NR | NR | NR | NR | NR | NR |
| V: | 309 (149/160) | 66.0 ( 10.2) | 29.6 (5.8) | April 2015 to December 2016 | NR | NR | NR | NR | NR | NR | |
| All: | 555 | ||||||||||
| Dial et al30 2018 | C: | 128 (64/64) | 61.5 (10.5) | 29.8 (5.8) | June 2013 to January 2015 | mean: 14.4 mths (SD 7.5) | 19 (14.8) | 83 (64.8) | 11 (8.6) | 18 (14.1) | 10 (7.8) |
| V: | 137 (65/72) | 61.2 (11.1) | 30.0 (6.0) | January 2015 to February 2016 | mean: 8.2 mths (SD 4.5) | 16 (11.7) | 83 (60.6) | 4 (2.9) | 23 (16) | 15 (10.9) | |
| All: | 265 | ||||||||||
| Patel et al14 2018 | C: | 112 (48/64) | 64.8 | 31.1 | April 2016 to September 2016 | mean: 11.3 mths (3.0 to 25.6) | 14 (12.5) | NR | NR | 12 (9.8) | 2 (1.8) |
| V: | 348 (138/210) | 63.6 | 30.6 | October 2016 to October 2017 | mean: 7.7 mths (3.2 to 19.1) | 34 (9.8) | NR | NR | 22 (6.3) | 13 (3.7) | |
| All: | 460 | ||||||||||
| Winkler et al25 2018 | C: TKA: THA: | 152 (48/104) 97 (47/50) |
27 (17.8) 63.5 (17.7) |
NR | 1 January 2012 to 31 December 2013 | At least 6 mths for both groups | 2 (1.3) | NR | 14 (9.2) | 40 (26.3) | NR |
| V: TKA: THA: | 191 (70/121) 133 (61/72) |
80 (41.9) 65 (11.9) |
NR | 1 January 2014 to 31 December 2015 | 11 (5.8) | NR | 24 (12.6) | 50 (26.2) | NR | ||
| All: | 573 | ||||||||||
| Khatri et al33 2017 | C: | 64 (44/20) | NR | NR | February 2014 to January 2016 for two groups | 6 mths for both groups | 23 (35.9) | 25 (39.1) | NR | NR | NR |
| V: | 51 (32/19) | 17 (33.3) | 22 (43.1) | NR | NR | NR | |||||
| All: | 115 | ||||||||||
| Otte et al26 2017 | C: TKA: THA: |
392 252 |
NR | NR | 1 May 2012 to 30 April 2013 | 3 mths for both groups | NR | NR | NR | NR | NR |
| V: TKA: THA: |
400 282 |
NR | NR | 1 May 2013 to 30 April 2014 | NR | NR | NR | NR | NR | ||
| All: | 1,326 | ||||||||||
| Assor27 2010 | C: | 73 (17/56) | 72 (7.6) | NR | 2002 to 2006 for both groups | mean: 5 yrs (3 to 7) for both groups | NR | NR | NR | NR | NR |
| V: | 62 (16/46) | 73 (8.2) | NR | NR | NR | NR | NR | NR | |||
| All: | 135 |
BMI, body mass index; C, control group; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; NR, not reported; THA, total hip arthroplasty; TKA, total knee arthroplasty; V, vancomycin group.